Standing Orders for Administering Influenza Vaccine to Adults 2018-2019

Purpose
To reduce morbidity and mortality from influenza by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) and the Department of Defense (DoD).

Policy
Under these standing orders, and with documented 2018-2019 seasonal influenza vaccination training, eligible nurses and other healthcare professionals working within their scope-of-practice may vaccinate adult patients who meet the criteria below.

Procedure
1. Assess Adults for Need of Vaccination against influenza
   - All adults are recommended to receive influenza vaccination each year.
   - Pregnant women are recommended to receive influenza vaccination each year. Administer inactivated influenza vaccine (IIV) to pregnant women in any trimester.
   - People who do not recall whether they received influenza vaccine this year should be vaccinated.

2. Screen for Contraindications and Precautions

Contraindications for use of all influenza vaccines
Do not give influenza vaccine to an adult who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components. For a list of vaccine components, refer to the manufacturer’s package insert or go to https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.

Contraindications only for use of live attenuated influenza vaccine (LAIV; FluMist, nasal spray)
Do not give live attenuated influenza vaccine (LAIV4; nasal spray) to a person who:
   - is pregnant
   - has immunosuppression (including that caused by medications or HIV)
   - is age 50 years or older
   - received influenza antivirals (e.g., amantadine, rimantadine, zanamivir, or oseltamivir) within the previous 48 hours or will possibly receive them within 14 days after vaccination
   - provides care for a severely immunosuppressed person who requires a protective environment

Precautions for use of all influenza vaccines
   - Moderate or severe acute illness with or without fever
   - History of Guillain-Barré syndrome within 6 weeks of a previous influenza vaccination

Precautions for use of LAIV only
   - Asthma
   - Other chronic medical conditions (e.g., other chronic lung diseases, chronic cardiovascular disease [excluding isolated hypertension], chronic renal or hepatic disease, hematologic disease, neurologic disease, and metabolic disorders, including diabetes mellitus)

DHA-IHD (877) GETVACC www.health.mil/vaccines

Adapted from Immunization Action Coalition (IAC). Technical content reviewed by the Centers for Disease Control and Prevention
Note regarding patients with egg allergy: People with egg allergy of any severity can receive any licensed and recommended influenza vaccine (i.e., any IIV or RIV) that is otherwise appropriate for the patient’s age and health status. For people with a history of severe allergic reaction to egg involving any symptom other than hives (e.g., angioedema, respiratory distress, lightheadedness, or recurrent emesis), or who required epinephrine or another emergency medical intervention, the selected vaccine should be administered in a medical setting (e.g., health department or physician office). Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.

3. Provide Vaccine Information Statements

Provide all patients with a copy of the current federal Vaccine Information Statement (VIS). Provide non-English speaking patients and/or parents/guardians with a copy of VIS in their native language, if one is available and desired; these can be found at www.cdc.gov/vaccines/pubs/vis. (For information about how to document that the VIS was given, see section 6 titled “Document Vaccination.”)

4. Prepare to Administer Vaccine

For vaccine that is to be administered intramuscularly, choose the needle gauge, needle length, and injection site according to the following chart:

<table>
<thead>
<tr>
<th>Gender and weight of patient</th>
<th>Needle gauge</th>
<th>Needle length</th>
<th>Injection site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male less than 130 lbs</td>
<td>22–25</td>
<td>5⁄8”–1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female or male 130–152 lbs</td>
<td>22–25</td>
<td>1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 153–200 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 153–260 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

*A 5⁄8” needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle to the skin.

For vaccine that is to be administered intranasally or intradermally, prepare the vaccine according to directions in the package insert.

6. Administer Vaccine according to the criteria and guidance in the table below:

<table>
<thead>
<tr>
<th>Type of vaccine</th>
<th>Age group</th>
<th>Dose</th>
<th>Route</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated influenza vaccine (IIV)</td>
<td>All ages</td>
<td>0.5 mL</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
<tr>
<td>IIIV-intradermal</td>
<td>18 through 64 years</td>
<td>0.1 mL</td>
<td>Intradermal (ID)</td>
<td>Insert needle of the microinjection system at a 90-degree angle in the deltoid area.</td>
</tr>
<tr>
<td>IIIV-high dose</td>
<td>65 years and older</td>
<td>0.5 mL</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
<tr>
<td>Adjuvanted inactivated influenza vaccine (aIIV)</td>
<td>65 years and older</td>
<td>0.5 mL</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
</tbody>
</table>

DHA-IHD (877) GETVACC www.health.mil/vaccines

Adapted from Immunization Action Coalition (IAC). Technical content reviewed by the Centers for Disease Control and Prevention.
Cell culture-based IIV (ccIIV) | All ages | 0.5 mL | Intramuscular (IM) | Administer vaccine in deltoid muscle.
---|---|---|---|---
Recombinant influenza vaccine (RIV) | 18 years and older | 0.5 mL | Intramuscular (IM) | Administer vaccine in deltoid muscle.
Live attenuated influenza vaccine (LAIV) | Healthy, younger than age 50 years (except pregnant women) | 0.2 mL (0.1 mL into each nostril) | Intranasal spray (NAS) | Spray half of vaccine into each nostril while the patient is in an upright position.

6. Document Vaccination

Document immunizations for service members in AHLTA and the Service Immunization Tracking System (MEDPROS, ASIMS, SAMS, or MRRS). Use AHLTA for beneficiaries. Document required immunization information including: the name of the vaccine, the date vaccine was administered, the manufacturer, lot number, the dosage, VIS version date, and the name of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt of the vaccine (e.g., medical contraindication, patient refusal, medical temporary exemption (MT)).

7. Be Prepared to Manage Medical Emergencies

Be prepared to manage a medical emergency related to the administration of vaccine by having a written emergency medical protocol available, as well as equipment and medications.

8. Report all rare or unexplained adverse reactions to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or by calling (800) 822-7967.

9. DoD-Approved Vaccines:

<table>
<thead>
<tr>
<th>DoD Categories</th>
<th>Name</th>
<th>Manufacturer</th>
<th>Presentation</th>
<th>Formulation</th>
<th>Approved use in ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 - 35 months</td>
<td>Flulaval®</td>
<td>GSK</td>
<td>PFS (0.5 mL)</td>
<td>Quad</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td>3 years and older</td>
<td>Flulaval®</td>
<td>GSK</td>
<td>MDV (5 mL)</td>
<td>Quad</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td></td>
<td>Fluarix®</td>
<td>GSK</td>
<td>PFS (0.5 mL)</td>
<td>Quad</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td>9 years &amp; older and 18 years &amp; older</td>
<td>Afluria®</td>
<td>Seqirus</td>
<td>PFS (0.5 mL)</td>
<td>Quad</td>
<td>≥ 5 years</td>
</tr>
<tr>
<td></td>
<td>Afluria®</td>
<td>Seqirus</td>
<td>MDV (5 mL)</td>
<td>Quad</td>
<td>≥ 5 years</td>
</tr>
</tbody>
</table>

*MDV = Multi-Dose Vial, PFS = Prefilled Syringe; MDVs contain thimerosal as a preservative. All flu vaccines require refrigeration between 2-8° C; do not freeze.

10. 2018-2019 Influenza Vaccine Composition:

- Trivalent vaccines:
  - A/Michigan/45/2015 (H1N1) pdm09-like virus
  - A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
  - B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)
- Quadrivalent vaccines:
  - Above three, plus B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage)
Standing Orders Authorization

This policy and procedure shall remain in effect for all patients of the ______________________________
Name of practice or clinic
until rescinded or until__________
Date
Medical Director’s signature_________________________ Signature date________ Effective date________

Adapted from Immunization Action Coalition (IAC). Technical content reviewed by the Centers for Disease Control and Prevention